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What We’re Talking About
When We Talk About Race*
Edward P. Havranek, MD, FACC,
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Denver, Colorado
It has been pointed out repeatedly (1,2) that reported
associations between race and illness should be subject to
careful scrutiny. Establishing race as an independent risk
factor for a disease is even more complicated than the
usually difficult task of establishing epidemiologic associa-
tion. Among the usual difficulties are selection of a repre-
sentative sample, collection of accurate data, identification
of appropriate controls, and adjustment for confounders.
Unlike other variables in epidemiologic studies, however,
race has complex social and biologic implications.
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Viewing race as a social construct is clearly important in
epidemiology. Race is linked to a wide range of socioeco-
nomic and cultural factors that impart important modifying
effects on health, disease, and the delivery of health care.
These factors include income, education, diet, health be-
liefs, access to health insurance, and exposure to discrimi-
nation (3). African American adults are approximately 2.5
times as likely as white Americans to have incomes below
the poverty level, and African American children are ap-
proximately four times as likely to live in families with
incomes below the poverty level. According to the 2000
U.S. Census, 78.5% of African Americans and 88.4% of
white Americans over the age of 25 are high school
graduates. Differences in college graduation rates are even
greater: 16.5% for African Americans and 28.1% for white
Americans. The 2000 Center for Disease Control National
Health Interview Survey found that although 12.5% of
white Americans lacked health insurance, the comparable
figure for African Americans was 20%. Apparent racial
differences may be markedly attenuated after accounting for
confounders such as these. For instance, nationwide studies
of patterns of care for heart failure (HF) have found lower
rates of angiotensin-converting enzyme inhibitor prescrip-
tion for African American patients (4,5). In contrast, a
recent study of Medicare patients (6), who presumably have
lower barriers to gaining access to care, found no racial
differences in rates of guideline-based therapy. Race should
not be used as a proxy for socioeconomic or cultural factors.
When differences in risk factors for a disease are the result
of measurable socioeconomic and cultural factors, this
causative link should be made explicit.
Race has been viewed in medicine as a biologic construct
as well. Race classifies humans on the basis of facial features,
hair type, and skin color. The boundaries of these classifi-
cations are never explicitly stated and vary across cultures.
Thus, there is no standardized method in the medical
literature of assigning race. Race may be assigned by the
investigator based on the subject’s appearance, or it may be
self-assigned by the subject. Self-assignment may be from
fixed sets of categories that vary among studies or from an
open-ended question. Although racial designations are
loosely associated with the continent of origin of an indi-
vidual’s ancestors, much of the medical literature implicitly
attaches a greater genetic significance to race than the
available data warrant. Estimates of the genetic variability
attributable to individual variation within populations range
from 85% to 95% (7,8). Of the remaining genetic variability,
only about half is attributable to between-continent differ-
ences. Thus, two individuals from different racial groups
may very well share more genes than two individuals from
the same racial group (9). It has been estimated that
approximately 30% of the variable genetic make-up of
African Americans is the result of admixture with people of
non-African origin (10). Seen in this light, race may have
relatively little value as a biologic construct. Exceptions may
exist, however. Adrenergic receptor (11) and G protein (12)
polymorphisms that may predispose one to HF are more
prevalent in African Americans compared with whites.
Although further work is needed to confirm the validity of
these findings, they may help explain why, for instance,
African Americans with hypertension appear to be more
likely to develop left ventricular hypertrophy (13). The fact
remains, however, that race is an imprecise categorization
scheme and is a poor proxy for genomic differences.
In this issue of the Journal, Ruo et al. (14) present
evidence that HF patients identified in the medical record as
African American are approximately half as likely as those
identified as white to have atrial fibrillation (AF). Among
1,373 randomly chosen patients hospitalized with HF
during a one-year period, 506 had AF. The prevalence of
AF was 19.7% in the African American patients and 38.3%
in the white patients. Although relative risks are not
reported, the odds ratio of 0.51 for racial prevalence in their
final multivariable model suggests that adjustment for age,
gender, known risk factors for AF, comorbidity, medica-
tions, and HF severity does not substantially alter this
relationship. The magnitude of the computed relative risk is
striking. How well has the current study avoided the pitfalls
of inadequate adjustment for confounding by socioeconomic
and cultural factors and of unwarranted assumption of
genetic explanations?
With respect to recognizing confounding by socioeco-
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nomic and cultural factors, they have studied a sample
drawn from a Kaiser Permanente managed care population
that has been demonstrated to be representative of the state
population. This makes it less likely that black–white
differences are the result of socioeconomic factors, but it is
unclear whether the African American patients in the study
are representative of African American patients in general.
Second, although the population studied is relatively ho-
mogenous from a socioeconomic standpoint, unmeasured
socioeconomic confounders are likely to have been present.
Ascertainment of detailed socioeconomic data from the
medical record is difficult, and more explicit adjustments
would not have been possible with the information available
to the investigators.
With respect to possible genetic explanations, the current
study is intriguing. First, the direction of the association
between race and AF runs counter to that which one might
expect if the relationship was based on socioeconomic and
cultural factors. The poorer socioeconomic status of African
Americans typically is associated with more severe impair-
ment of health status and poorer outcomes, yet the lower
incidence of AF among African Americans is a marker of
less severe HF. Second, the authors have studied a condi-
tion, AF, for which genetic predisposition exists. Familial
forms of AF have been described (15), and genetic loci for
the arrhythmia have been mapped to chromosome 10 (16),
chromosome 6 (17), and perhaps to others (18). Although
the existence of a heritable form of AF may suggest the
possibility that the findings of the present study reflect
distinct genetic differences, the reality is much less clear.
The genetic forms identified thus far account for a small
minority of cases of AF, and none of the existing AF
chromosomal links have been specifically associated with
race. Although current understanding of the contribution of
genotype to the development of AF is incomplete, it would
be premature to conclude that racial differences in AF
incidence reflect genetic differences rather than a finding
confounded by socioeconomic or cultural factors.
If confirmed, the findings of Ruo et al. (14) may be more
important for generating future mechanistic studies than for
elucidating epidemiology. Such future studies would collect
data that more explicitly account for the socioeconomic
status of the patients involved. If predisposition to AF or
protection from AF can be mapped to a specific gene or
genes, genotyping performed as part of these studies should
aid in the identification of relevant polymorphisms. The
current study, although limited in its ability to adjust for
socioeconomic and cultural confounding and to assess for
genetic polymorphisms directly, credibly neither neglects
the social nature of race nor uncritically assumes a biologic
basis for race. As our society struggles to eliminate race-
associated disparities in care and eagerly awaits the advent of
genomic medicine, it is absolutely critical that we all know
what we’re talking about when we talk about race.
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